Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis
Overview
- Phase
- Phase 4
- Intervention
- Oxaliplatin plus Capecitabine
- Conditions
- HER-2 Positive Gastric Cancer
- Sponsor
- Hebei Medical University
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- progression-free survival(PFS)
- Last Updated
- 11 years ago
Overview
Brief Summary
Stage I：preoperative therapy
- Capecitabine plus oxaliplatin with herceptin is superior to surgery alone for patients with potentially resectable HER-2 positive gastric cancer with liver metastasis; Stage II: Perioperative therapy
- Perioperative Capecitabine plus oxaliplatin with herceptin is superior to adjuvant Capecitabine plus oxaliplatin alone for patients with potentially resectable HER-2 positive gastric cancer with liver metastasis;
Detailed Description
The investigators assessed whether the addition of a perioperative regimen of XELOX regimen with herceptin to improves R0 resection rate and survival among patients with potentially resectable HER-2 positive gastric cancer with liver metastasis.
Investigators
Qun Zhao
Principal Investigator
Hebei Medical University
Eligibility Criteria
Inclusion Criteria
- •1.Pathological tissue were gastric cancer by gastric and liver biopsy.
- •2.Immunohistochemistry confirmed HER-2 (+)or FISH(+).
- •3.gastric cancer with liver metastasis were not able to resectable lesions.
- •4.Patients•had not received radiotherapy past and not other organ metastasis and peritoneal metastasis.
- •5.ECOG performance status 0-
- •6.Inadequate hematopoietic function： Hemoglobin≥90g/L; ANC≥1,500/mm3;Platelet≥100,000/mm3 7.Inadequate organ function which is defined as below: Total bilirubin≤1.5 pper limit of normal range (ULN); ALT / AST≤2.5 upper limit of normal range (ULN) (≤5.0 x ULN if hepatic metastasis); serum creatinine≤1.5 pper limit of normal range (ULN), Serum albumin≥30g/L.
- •8.expectancy must be more than 3 months. 9.the random blood or urine pregnancy test in fertile woman must be the negative results in pregnancy test in 7 days.
- •10.Patients for male and female used reliable contraception contraceptive method until the end of study 30 days later.
- •11.The operation can complete the D2 operation(LNM≥15).
- •12.LVEF≥50%
Exclusion Criteria
- •Patients with other extrahepatic metastasis Include peritoneal metastasis.
- •Patients with other malignancy in 5 years.
- •Patients with peripheral nerve disease,two hydrogen pyrimidine dehydrogenase( DPD )deficiency,upper digestive tract obstruction or from malabsorption syndrome.
- •5.Patients with hypertension failed to control, active bleeding, 3\~4 proteinuria, heal the wound, romboembolism, heart failure, clinical symptoms of heart disease.
- •6.Patients have obvious peripheral nervous system disorders,mental disorders and disorders of the central nervous system history.
- •7.Patients have history of organ transplantation.
- •8.Patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study.
- •9.Patients combined antitumor drug outside the research program.
Arms & Interventions
Herceptin
drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles. To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis
Intervention: Oxaliplatin plus Capecitabine
Herceptin
drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles. To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis
Intervention: Herceptin
Outcomes
Primary Outcomes
progression-free survival(PFS)
Time Frame: 2 years
Secondary Outcomes
- Objective response rate (ORR)(within 3 weeks after surgery)